Scholar Rock Holding Corp (SRRK) Stock Price, Quote & News

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively targ...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 259 3860

Website: www.scholarrock.com

Address:

301 Binney Street, 3rd Floor, Cambridge, United States

DiagonalD2 Dec. 26 at 3:44 PM

$SRRK Conditions are shifting toward markets rewarding operational proof over narrative ambition. Operating rhythm should stabilize as learning cycles compress. Demonstrated durability would lengthen investor time horizons. Upside remains tied to tangible progress, not assumptions.

0 · Reply

BillionerOfKing Dec. 24 at 7:37 PM

$SRRK Current Stock Price: $45.86 Contracts to trade: $45 SRRK Jan 16 2026 Call Entry: $1.85 Exit: $2.59 ROI: 40% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Bulldog344 Dec. 20 at 1:22 PM

$SRRK Huge potential to prevent muscle loss

0 · Reply

JarvisFlow Dec. 17 at 5:58 PM

Barclays has updated their rating for Scholar Rock Holding ( $SRRK ) to Overweight with a price target of 52.

0 · Reply

Thinkingman91 Dec. 17 at 4:32 PM

$SRRK last one. This has the potential to 10x your money

3 · Reply

Thinkingman91 Dec. 17 at 4:31 PM

$SRRK ello

0 · Reply

Thinkingman91 Dec. 17 at 4:31 PM

$SRRK I haven’t forgot you. This is my favorite sleeper stock for the future. Let’s get this dip out the way

0 · Reply

Thinkingman91 Dec. 15 at 4:43 PM

$SRRK what ya think

0 · Reply

TripleGateCptl Dec. 15 at 4:36 AM

$SRRK ....some people on the ALDX page enjoyed a good discussion... https://x.com/TripleGateCaptl/status/2000422431303835885?s=20

0 · Reply

AkamaiJet Dec. 12 at 9:04 PM

$SRRK calls realised gain: +$5,767

0 · Reply

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 3:33 PM EST - 4 weeks ago

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 18, 2025, 8:00 AM EST - 6 weeks ago

Scholar Rock to Present at Upcoming Investor Conferences

Nov 14, 2025, 2:01 PM EST - 6 weeks ago

Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 7:00 AM EST - 6 weeks ago

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 13, 2025, 3:05 PM EST - 6 weeks ago

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks

CARS CHH HIMS LCID MPW NOG SPHR

Nov 10, 2025, 11:28 AM EST - 7 weeks ago

Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)

Nov 4, 2025, 8:00 AM EST - 2 months ago

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Oct 23, 2025, 8:00 AM EDT - 2 months ago

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Sep 23, 2025, 5:02 PM EDT - 3 months ago

Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions

Sep 23, 2025, 11:32 AM EDT - 3 months ago

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

Sep 23, 2025, 8:16 AM EDT - 3 months ago

Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

FLY

Sep 23, 2025, 7:12 AM EDT - 3 months ago

US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:00 AM EDT - 3 months ago

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Aug 14, 2025, 8:00 AM EDT - 4 months ago

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Aug 6, 2025, 11:33 PM EDT - 5 months ago

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Jul 21, 2025, 8:00 AM EDT - 5 months ago

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Jun 24, 2025, 6:25 PM EDT - 6 months ago

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Jun 23, 2025, 8:00 AM EDT - 6 months ago

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Jun 18, 2025, 10:47 AM EDT - 7 months ago

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

LLY

Jun 18, 2025, 7:33 AM EDT - 7 months ago

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Jun 18, 2025, 7:12 AM EDT - 7 months ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:00 AM EDT - 7 months ago

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Jun 5, 2025, 8:00 AM EDT - 7 months ago

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 8:00 AM EDT - 7 months ago

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

May 28, 2025, 8:00 AM EDT - 7 months ago

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 12:30 PM EDT - 8 months ago

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 8 months ago

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 7, 2025, 8:00 AM EDT - 8 months ago

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Apr 28, 2025, 6:50 AM EDT - 8 months ago

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Mar 25, 2025, 7:30 AM EDT - 10 months ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 17, 2025, 12:21 PM EDT - 10 months ago

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Mar 16, 2025, 7:00 PM EDT - 10 months ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 27, 2025, 1:23 PM EST - 10 months ago

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 10 months ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 25, 2025, 4:15 PM EST - 11 months ago

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 21, 2025, 8:00 AM EST - 11 months ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 19, 2025, 10:41 AM EST - 11 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 10, 2025, 8:00 AM EST - 11 months ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Jan 30, 2025, 8:37 AM EST - 11 months ago

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Jan 29, 2025, 8:05 AM EST - 1 year ago

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Jan 29, 2025, 8:00 AM EST - 1 year ago

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Jan 15, 2025, 2:23 PM EST - 1 year ago

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Jan 8, 2025, 4:00 PM EST - 1 year ago

Scholar Rock Highlights 2025 Strategic Priorities

Jan 2, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 11:51 AM EST - 1 year ago

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Nov 12, 2024, 11:09 AM EST - 1 year ago

Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 1 year ago

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

Nov 4, 2024, 8:00 AM EST - 1 year ago

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

DiagonalD2 Dec. 26 at 3:44 PM

0 · Reply

BillionerOfKing Dec. 24 at 7:37 PM

0 · Reply

Bulldog344 Dec. 20 at 1:22 PM

$SRRK Huge potential to prevent muscle loss

0 · Reply

JarvisFlow Dec. 17 at 5:58 PM

Barclays has updated their rating for Scholar Rock Holding ( $SRRK ) to Overweight with a price target of 52.

0 · Reply

Thinkingman91 Dec. 17 at 4:32 PM

$SRRK last one. This has the potential to 10x your money

3 · Reply

Thinkingman91 Dec. 17 at 4:31 PM

$SRRK ello

0 · Reply

Thinkingman91 Dec. 17 at 4:31 PM

$SRRK I haven’t forgot you. This is my favorite sleeper stock for the future. Let’s get this dip out the way

0 · Reply

Thinkingman91 Dec. 15 at 4:43 PM

$SRRK what ya think

0 · Reply

TripleGateCptl Dec. 15 at 4:36 AM

$SRRK ....some people on the ALDX page enjoyed a good discussion... https://x.com/TripleGateCaptl/status/2000422431303835885?s=20

0 · Reply

AkamaiJet Dec. 12 at 9:04 PM

$SRRK calls realised gain: +$5,767

0 · Reply

Thinkingman91 Dec. 12 at 7:44 PM

$SRRK I still don’t think you clear $48

0 · Reply

Whiskeyunderthebed Dec. 12 at 4:47 PM

$SRRK hitting higher highs

0 · Reply

OptionRunners Dec. 12 at 4:40 PM

$SRRK buyer of the April 17th 2026 $45/$35 1x2 put ratio spreads 1,250/2,500 times for $1.75

0 · Reply

PooPooPewPew Dec. 11 at 11:17 PM

$SRRK still holding, should move up nicely once we get an update on production facility or alternative facility readiness.

0 · Reply

Whiskeyunderthebed Dec. 11 at 9:51 PM

$SRRK after hours... is a killer

0 · Reply

AkamaiJet Dec. 11 at 7:37 PM

$SRRK $55 EOY?

0 · Reply

Whiskeyunderthebed Dec. 11 at 4:25 PM

$SRRK this is looking really scary.

0 · Reply

BillionerOfKing Dec. 10 at 3:19 AM

$SRRK Current Stock Price: $44.63 Contracts to trade: $45 SRRK Dec 19 2025 Call Entry: $1.40 Exit: $2.21 ROI: 58% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Tdorsey1776 Dec. 9 at 10:37 PM

$SRRK Come back to poppa to add

0 · Reply

Whiskeyunderthebed Dec. 9 at 3:48 PM

$SRRK Love the slow creep up and away!

1 · Reply

Thinkingman91 Dec. 5 at 7:05 PM

$SRRK now we watch and see

0 · Reply

Thinkingman91 Dec. 5 at 7:04 PM

$SRRK 47.xx and change bet that’s the top until warrants are exercised

0 · Reply

Market Cap	4.61B
Revenue (ttm)	0.00
Net Income (ttm)	-246.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.41

Volume	650,700
Avg Vol	1,774,370
Day's Range	N/A - N/A
Shares Out	102.01M
Stochastic %K	27%
Beta	0.60
Analysts	Strong Sell
Price Target	$47.92